- Research article
- Open Access
Protection induced by a glycoprotein E-deleted bovine herpesvirus type 1 marker strain used either as an inactivated or live attenuated vaccine in cattle
- Sonia Alejandra Romera†1, 7, 8Email author,
- Mariana Puntel†2,
- Valeria Quattrocchi1,
- Paula Del Médico Zajac1,
- Patricia Zamorano1, 7, 8,
- Javier Blanco Viera3,
- Consuelo Carrillo4,
- Shafiqul Chowdhury5,
- Manuel V Borca6 and
- Ana M Sadir1, 7, 8
© Romera et al.; licensee BioMed Central Ltd. 2014
Received: 11 September 2013
Accepted: 17 December 2013
Published: 8 January 2014
Bovine herpesvirus type 1 (BoHV-1) is the causative agent of respiratory and genital tract infections; causing a high economic loss in all continents. Use of marker vaccines in IBR eradication programs is widely accepted since it allows for protection of the animals against the disease while adding the possibility of differentiating vaccinated from infected animals.
The aim of the present study was the development and evaluation of safety and efficacy of a glycoprotein E-deleted (gE-) BoHV-1 marker vaccine strain (BoHV-1ΔgEβgal) generated by homologous recombination, replacing the viral gE gene with the β-galactosidase (βgal) gene.
In vitro growth kinetics of the BoHV-1ΔgEβgal virus was similar to BoHV-1 LA. The immune response triggered by the new recombinant strain in cattle was characterized both as live attenuated vaccine (LAV) and as an inactivated vaccine. BoHV-1ΔgEβgal was highly immunogenic in both formulations, inducing specific humoral and cellular immune responses. Antibody titers found in animals vaccinated with the inactivated vaccine based on BoHV-1ΔgEβgal was similar to the titers found for the control vaccine (BoHV-1 LA). In the same way, titers of inactivated vaccine groups were significantly higher than any of the LAV immunized groups, independently of the inoculation route (p < 0.001). Levels of IFN-γ were significantly higher (p < 0.001) in those animals that received the LAV compared to those that received the inactivated vaccine. BoHV-1ΔgEβgal exhibited an evident attenuation when administered as a LAV; no virus was detected in nasal secretions of vaccinated or sentinel animals during the post-vaccination period. BoHV-1ΔgEβgal, when used in either formulation, elicited an efficient immune response that protected animals against challenge with virulent wild-type BoHV-1. Also, the deletion of the gE gene served as an immunological marker to differentiate vaccinated animals from infected animals. All animals vaccinated with the BoHV-1ΔgE βgal strain were protected against disease after challenge and shed significantly less virus than control calves, regardless of the route and formulation they were inoculated.
Based on its attenuation, immunogenicity and protective effect after challenge, BoHV-1ΔgEβgal virus is an efficient and safe vaccine candidate when used either as inactivated or as live attenuated forms.
Bovine herpesvirus-1 (BoHV-1) is an important pathogen of cattle and responsible for a wide variety of clinical diseases, including conjunctivitis and upper respiratory tract infection known as infectious bovine rhinotracheitis (IBR), reproductive tract lesions, abortion in pregnant cows, and systemic infection in the newborn [1–3]. In addition, BoHV-1 has been recognized as an important component of the bovine respiratory disease (BRD) complex [1, 4]. The BoHV-1 infection in cattle is responsible for considerable economic losses due to decreased milk production, weight loss and abortion.
The virus genome consists of a linear double-stranded DNA molecule of about 135.3 kb that encodes for approximately 70 proteins . Twelve of them (gB, gC, gD, gE, gG, gI, gH, gK, gL, gM, UL49.5 and Us9) are envelope proteins, of which the first ten are glycosylated . Envelope glycoproteins gE and gI form complexes and gE is involved in viral intercellular spread (cell-to-cell spread). BoHV-1 gE open reading frame (ORF) is predicted to contain 575 amino acid (aa) residues with a 28 aa cleavable signal sequence. The structure of glicoprotein E (gE) corresponds to a type I transmembrane glycoproteins. The glycoprotein contains three distinct domains: a 387 aa long hydrophilic extracellular domain (ecto-domain), a 33 aa long hydrophobic transmembrane domain and a 125 aa long highly charged cytoplasmic domain/tegument domain. The mature gE is phosphorylated and glycosylated with an apparent molecular mass of about 92 kD.
Attenuated live viruses or inactivated virions are used widely as vaccines to control the disease. Thus, BoHV-1-specific antibodies can be found in bovines on all continents; its prevalence varies greatly depending on herd size and management. Classical vaccines complicate serological diagnosis and determination of the true prevalence of infection. Marker and conventional vaccines can prevent disease but not latent infection. Due to the current restrictions in international trade for products derived from seropositive animals a number of European countries have eradicated BoHV-1 with very high costs involved. In countries with a high prevalence of infection, including the United States, the control of IBR is associated with the immunization of cattle with marker vaccines. In this context, the ability to differentiate infected from vaccinated animals (DIVA) has become critical issue. Gene-deleted marker vaccines offer the advantage of deletion of specific viral genes that are non-essential for viral replication [6, 7] while inducing a substantial protein-specific immune response. Currently, vaccines used in BoHV-1 control programs utilize highly attenuated BoHV-1 strains marked by a deletion of the gE gene . Glycoprotein E is considered a virulence factor of all known members of the subfamily Alphaherpesvirinae[9–11].
Live and killed gE-deleted marker vaccines are now widely used in Europe, in combination with gE-based diagnostic tests to monitor cattle. The gE-deleted mutants generated thus far include derivations of herpes simplex virus (HSV), pseudorabies virus, equine herpesvirus 1 and BoHV-1; these were shown to be attenuated in mice, swine, foals and calves, respectively [8, 9, 12, 13]. Notably, expression of gE and gI is required for full pathogenic potential in animals but is not required for growth in tissue culture , thus allowing for it replication in cell culture. In infected animals, gE is required for anterograde neuronal spread and neurovirulence. Accordingly, an interesting safety feature that comes from using LAV based on gE-deleted viruses is that the virus cannot spread in an anterograde direction from sensory neurons in trigeminal ganglia to respiratory mucosa. Furthermore, gE induces specific antibodies both in the context of inactivated vaccines or as infectious virus, thus facilitating serological differentiation of animals immunized with a gE-deleted marker vaccine from infected cattle . Safety and efficacy of both the live and the inactivated gE-deleted vaccines that are available have been tested thoroughly [15–22].
In this report, we present data regarding the development of a gE-deleted and βgal expressing BoHV-1 (BoHV-1ΔgEβgal) strain and its use as either an inactivated immunogen or as an LAV in cattle. Our results demonstrate that BoHV-1ΔgEβgal virus is an efficient vaccine candidate when used either as inactivated or as live attenuated form.
Virus and cells
BoHV-1 Los Angeles (LA) (American Type Culture Collection, VR-188) and BoHV-1ΔgEβgal strains were propagated in Madin Darby Bovine Kidney (MDBK) cells grown in Eagle’s Minimal Essential Medium (MEM), supplemented with 10% fetal bovine serum (FBS).
Construction of the recombinant plasmid
Virus DNA was extracted from cell-free supernatant virus preparations following a standard phenol/chloroform procedure using sodium dodecyl sulfate (SDS) and proteinase K lysis, phenol/ether extraction, and ethanol precipitation . Discrete flanking regions corresponding to gE gene were amplified by PCR from this material. Primer sequences were based on the published BoHV-1 glycoprotein E (gE) gene sequences [GenBank Accession Number NC 001847]. Primers were designed to add restriction sites in order to facilitate further cloning. The left flanking region of gE (L fragment) was obtained using primers gE1 (5′-GCGAGCAGCGGGAGCGGGGCC-3′),; and gE2(5′-GGGGCGGATCCGTGGGTTGCA-3′), which introduced a Sal I and a Bam HI sites, respectively. The right flanking region of gE (R fragment) was amplify using primers gE3(5′- AGCTTGGATCCCGGCCGCACC- 3′) and gE4 (5′- CCTCAGAATTCGGGGTCTCGG- 3′), which introduced a Bam Hi and an EcoR I sites to amplified fragment, respectively.
DNA fragments corresponding to the left (L) and right (R) gE flanking regions obtained by PCR were digested with the appropriate enzymes and cloned sequentially into the pUC19 vector (Clontech). First, the L product (734 bp long, corresponding to position 120956 to 121714 of the BoHV-1 genome) was cloned between the SalI and BamHI sites (recombinant plasmid pUCL), and then the R product (632 bp long, corresponding to position 123375 to 124008 of the BoHV-1 genome) was cloned between the BamHI and EcoRI sites (recombinant plasmid pUCLR), using a BamHI site that linked both L and R fragments. The blunt 4.5 kb fragment, which contains the bacterial β-gal gene under the control of the human cytomegalovirus immediate early promoter (HCMV-IE), was inserted into the blunted BamHI site of pUCLR. The resulting gE-deletion/β-gal insertion plasmid (pUCLRβ-gal) carried a deletion of 1,640 bp of BoHV-1 DNA, and the insertion of the β-gal gene controlled by the human cytomegalovirus immediate early promoter. In pUCLRβ-gal, the β-gal gene is flanked by virus-specific sequences required for recombination with the viral DNA: a 734 bp upstream sequence (L) containing part of the gE promoter and the first 23 bp of the coding sequence, a 632 bp downstream sequence (R) containing the last 67 bp at the 3′ extreme, and the complete ORF of the US9 gene (474 bp). Identity of both fragments corresponding to L and R were confirmed by sequencing (Fmol, Promega) (data not shown).
Generation of recombinant BoHV-1 gE-deleted βgal (BoHV-1ΔgEβgal) virus
To generate the BoHV-1 gE-deleted recombinant virus, MDBK cells were co-transfected with a ScaI linearized pUCLRβ-gal plasmid DNA together with a full-length DNA derived from BoHV-1 LA strain. Briefly, a mixture of 2 μg of parental BoHV-1 LA DNA, 0.2 μg of ScaI linearized pUCLRβgal vector and 16 μl of Lipofectamine (Gibco BRL, Life Technologies) was added onto a 60% confluent MDBK cell monolayergrown in a 6-well plate, and then incubated for 8 hours at 37°C in a CO2-controlled atmosphere. A media change was then performed using MEM containing 5% FBS and the plates were incubated for 16 hours in the same conditions described above. Each transfected cell monolayer was trypsinized and transferred to a 25 cm2 flask containing 5% FBS MEM and incubated until cytopathic effects (CPE) were observed. To determine the dilution of the inoculum for the Bluo-gal screening assay, the co-transfection products were titrated by plaque forming units (PFU) and frozen until the screening assay was performed.
Purification of the recombinant virus
Co-transfection products were examined for their β-gal expression by histochemical staining of infected cells. The recombinant viruses able to form blue plaques in the presence of the β-galactosidase substrate (halogenated indolyl-β-D-galactoside) were plaque purified five times under an agar overlay . Recombinant viruses expressing β-gal activity were selected by the appearance of blue plaques.
Molecular characterization of the recombinant virus
The recombinant virus was further characterized by PCR (gE-specific primers: gE7: 5′-CGCCCGTCTTTCTCCCAG-3′ and gE8: 5′-GCGGGACGAGGAGAGGGA-3′) and by Southern blot analysis targeting a part of the gE ORF. Lack of gE protein expression in BoHV-1ΔgEβgal infected cell lysates done by Western blot.
Southern blot hybridization
Genomic DNA extracted from purified wild-type and recombinant BoHV-1 viruses were digested with HindIII and the corresponding fragments were separated by electrophoresis in a 0.6% agarose TBE gel, then transferred to a nitrocellulose membrane (Zprobe, Bio-Rad). . The membrane bearing the immobilized DNA fragments was blocked with 2x SSC solution and fixed by heating at 80°C for 30 minutes. Hybridization was performed separately with three specific probes (L, R, y gE) previously obtained by PCR and labeled with 32S (Prime-a-Gene Labeling System, Promega).
gE-specific immunoblot analyses
Polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) and additional immunoblot analyses were performed using mock and virus-infected cells. Briefly, either mock (non-infected MDBK cells) and virus-infected cells were concentrated by ultracentrifugation at 12,000 g for 1 h at 47°C, resuspended in sample buffer (50 mM Tris–HCl, pH 7.5, 1 mM PMSF, 8 M urea, 1% SDS, 2 mM DTT and 2% β-Mercaptoethanol), boiled for 10 minutes, separated by gel electrophoresis in 12.5% polyacrylamide gels and blotted on to Immobilon P membranes (Millipore). Membranes were blocked overnight in phosphate buffered saline and 0.05% Tween 20 (PBST) containing 5% skim milk (all subsequent steps were performed using this buffer). Then, they were incubated for 2 hours at 37°C with the corresponding monoclonal antibodies: anti-gE, MAb3 (kindly provided by Dr. J.T. Van Oirschot from the Institute of Animal Science and Health, Lelystad, Netherlands), or anti-gD (kindly provided by Dr. L.A. Babiuk from the Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada). After three washes with PBST, membranes were incubated with peroxidase-labeled anti-mouse IgG rabbit antiserum (KLP Inc) for 1 hour at 37°C. After washing three times, antibody binding was visualized by chemiluminescence (Renaissance kit, NEN Life Science) after exposure to an X-ray film (CurixOrto ST-G2, AGFA).
Virus growth kinetics
The growth kinetics of the BoHV-1ΔgEβgal strain in MDBK cells was compared to that of the parental BoHV-1 LA strain. A series of replicate cultures of MDBK cells were infected separately with a MOI of 0.1 per cell of recombinant BoHV-1ΔgEβgal or the parental BoHV-1 LA strain. Infected cultures were harvested at successive post-infection intervals and frozen in aliquots until titration. Virus titration was performed by the end-point dilution method of Reed & Muench, in three independent repetitions.
Inactivated vaccine formulation
BoHV-1 LA or BoHV-1ΔgEβgal were propagated according to the conditions described earlier . Preparations were inactivated by treatment with 1% (v/v) 0.1 M binary bromoethylenimine (BEI) for 25 h at 37°C. One volume of inactivated virus suspension was mixed with one volume of INTA mineral oil adjuvant (formulated with Arlacel C, Markol 52 and Tween 80), to produce a water-in mineral oil emulsion according to Smitssart et al..
The animal experiments reported in this manuscript have been performed following internationally recognized guidelines with the approval of the Institutional Committee for Care and Use of Experimental Animals, CICUAE-CICVyA. INTA, Argentina.
Vaccination experiments were performed using 12 to 18 month-old Holando and Angus × Hereford calves with undetectable BoHV-1 serum antibodies (evaluated by ELISA and virus neutralization tests).
All challenge experiments using virulent BoHV-1 LA, and inoculations using attenuated BoHV-1ΔgEβgal (dose: 108.25 TCID50/mL) were performed in a type II biosafety animal facility.
Viral challenge was performed using 2 ml virulent BoHV-1 LA (107.5 TCID50/ml) into each nostril, by intranasal inoculation (IN) with an ultrasonic nebulizer (ELECTROLAB AP-300).
Evaluation of BoHV-1ΔgEβgal as either inactivated and attenuated vaccines
Vaccination time (dpv) [route, vol.]
BoHV-1 antibodies (dpv)
BoHV-1 sheeding (dpv/dpc)
inactivated BoHV-1ΔgEβgal vaccine
0, 21 [SC, 3 ml]
0, 14, 21, 30, 67, 150 and 186
0, 3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc
0, 21 [SC, 3 ml]
attenuated BoHV-1ΔgEβgal vaccine
Group 1: 0 [IN, 4 ml]
0, 7, 19, 34 and 42
1 to 42dpv
Group 2: 0 [IM, 4 ml]
3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc
attenuated BoHV-1ΔgEβgal vaccine SAFETY
Group 3: 0 [IV, 4 ml]
Safety assessment for BoHV-1ΔgEβgal as a life attenuated vaccine
The safety test was performed in pregnant cows. Five pregnant cows (being in the third to sixth month of pregnancy) were IV infected with attenuated BoHV-1ΔgEβgal virus (4 ml of the viral suspension with a titer of 108.25 TCID50/ml). Animals were clinically observed until they gave birth and serologically evaluated until 370 dpv. Likewise, newborn calves were also evaluated in regards to their clinical and immune conditions, as well as the virus shedding.
Detection of virus neutralizing antibodies
Virus neutralization (VN) was performed using primary fetal bovine testis (FBT) cell cultures in 96-well microtiter plates using the constant virus-variable serum method [26, 27]. Each dilution was tested in four wells containing FBT cell monolayers an adsorbed for 1 hour, the unabsorbed virus was removed and MEM with 5% FBS, was added. Plates were then incubated for 3 days at 37°C and the number of wells and serum dilution showing cytopathic effect was scored. Log10 of the reciprocal value of the highest serum dilution in which CPE was prevented was considered the virus neutralization titer.
Detection of anti-BoHV-1 and anti-gEantibodies in serum
Total antibodies against BoHV-1 in bovine serum were measured by an indirect ELISA as described elsewhere . Titers for bovine sera were expressed as Log10 of the reciprocal of the highest serum dilution which gives readings of absorbance greater or equal to 40% of the positive control measuring at an OD of 405 nm. Detection of gE-specific antibodies was performed using a commercial ELISA for BoHV-1 that allows for the detection of gE-specific antibodies (HerdChek Anti-IBR gE/IDEXX Laboratories), according to the manufacturer’s directions.
Detection of IgG1/IgA antibodies in nasal swabs
The mucosal immune response was determined using a specific ELISA for the detection of IgG1 and IgA. Briefly, nasal swabs were collected and frozen at -80°C. The antigen was prepared as described before (Romera et al., ).
BoHV-1-specific lymphoproliferation assay
Whole blood samples were collected by venipuncture in syringes containing heparin. Lymphocyte-enriched cells were isolated from the buffy coat as described elsewhere  by centrifugation on Lymphoprep (Nycomed Pharma A.S.). Cells were washed twice in RPMI + 5% FBS. UV light-inactivated suspensions of virus-infected MDBK cells (5 μg/ml) and control MDBK cells were used as antigens. The corresponding inactivated antigen was added to a 100 μl volume of medium containing 2 × 105 lymphocytes, performed in triplicate in a 96-well plate format. One microgram of the mitogen Concavalin A (Sigma, St Louis, USA) was added to the positive control wells. The lymphocyte cultures were incubated for 4 days at 37°C in a humidified atmosphere containing 5% CO2. Twenty hours before harvesting, 4 μCi of [3H] tymidine was added to each well. Cell proliferation was measured as [3H] tymidine uptake in a scintillation counter (LKB, Wallac, 1219 Rackbeta) and results were obtained as counts per minute (CPM). The values are the mean of the triplicate values and are expressed as stimulation index (SI), where SI = mean CPM of antigen-stimulated lymphocytes/mean CPM of MDBK-stimulated lymphocytes). A threshold value of SI = 3 was established.
Interferon Gamma assay
The capacity of mononuclear cells to secrete interferon γ (IFNγ) in response to a specific in vitro stimulation with inactivated BoHV-1 viral antigen was evaluated by a indirect sandwich ELISA. Briefly, 1.5 × 106 mononuclear cells were diluted in 100 μl of RPMI 10% FBS per well, in sterile microplates of 96 “U” bottom wells. The supernatant was added on Immulon II microplates, previously sensitized ON with anti bovine IFNγ monoclonal antibody (mAbs), and blocked with PBST 0.1% BSA. A reference curve was performed using IFNγ standard at known concentrations. Detection of the captured IFNγ was done using a rabbit anti-bovine IFNγ serum, diluted in 0.1% PBST-BSA. In order to improve the sensibility of the assay, plates were later incubated with biotin-labeled rat anti-rabbit IgG and developed using disodium p-nitrophenyl phosphate (PPN) as substrate. Optical densities (OD) at A405 were measured 25 minutes after the addition of the substrate.
Comparison of the vaccine profiles obtained throughout the experimental period was performed using an analysis of variance (ANOVA) for repeated measures with the Greenhouse and Geisser correction of the significance levels (fixed at 5%). The post-ANOVA comparisons were performed using the Bonferroni test with the same level of significance. All the statistical calculations were performed using the SAS program (release 6.04), following the G.M.L. procedure .
Construction of a gE deletion vector
Development of a BoHV-1 gE-deleted virus mutant (BoHV-1ΔgEβgal)
To generate the gE deletion mutant virus, the recombinant vector pUCLRβgal was co-transfected with BoHV-1 LA DNA into MDBK cells. The first screening was based on βgal expression. Selected viruses (blue plaque +) were further evaluated by PCR amplification using specific primers for gE regions (Figure 1e). The intended gE gene deletion and insertion of the βgal gene at the gE locus was further confirmed by Southern blot analysis with a gE-specific probe (Figure 1f). The absence of the 1639 bp gE fragment and the presence of a recombinant βgal fragment with the anticipated size of 4.5 kb demonstrated that the intended recombination had taken place in a site-specific manner. Western blot analysis using a BoHV-1 gE-specific MAb3 confirmed the deletion of the gE protein in the BoHV-1ΔgEβgal virus while a 92- to 95-kd BoHV-1 gE product was detected in BoHV-1 cell extracts (Figure 1g). The L and R fragments of BoHV-1ΔgEβgal were sequenced. No difference with wt virus were found.
Assessment of BoHV-1ΔgEβgal virus as an inactivated vaccine
Animals (n = 5/group) were subcutaneously vaccinated at days 0 and 21 with either a vaccine formulated with BoHV-1ΔgEβgal or wild-type BoHV-1 LA strain. At 186 dpv, the two vaccinated groups and a mock-vaccinated group (n = 6) were IN challenged with 107.5 TCID50/ml virulent BoHV-1 LA strain by aerosol exposure.
Similarly, neutralizing antibodies were first detected in vaccinated bovines at 30 dpv, (titers of 2.04 and 1.8 for BoHV-1ΔgEβgal-immunized and BoHV-1 LA-immunized groups, respectively). The neutralizing antibody titers before challenge ranged between 1.2 and 1.1 (Figure 3a). No significant differences were found in the responses elicited by BoHV-1ΔgEβgal and BoHV-1 LA as inactivated antigens. Nasal swabs were analyzed for isotype profiles of the virus-specific antibody responses at the time of challenge. We found that 5/5 animals vaccinated with BoHV-1 and 4/5 animals vaccinated with BoHV-1ΔgEβgal exhibited anti-BoHV-1 IgG1 antibodies in nasal swabs (titer = 1.6), while no IgA antibodies were detected in the same samples (data not shown).
Assessment of the gE-specific antibody response could be effectively utilized to differentiate animals vaccinated with inactivated BoHV-1ΔgEβgal, inactivated BoHV-1 LA, as well as those infected with BoHV-1 LA virus. At 14 dpv, groups that were BoHV-1ΔgEβgal-vaccinated, mock-vaccinated, or sentinel animals were found to be negative for gE-specific antibodies. However, these animals developed anti-gE antibodies by 216 dpv, 30 days after challenge. Additionally, gE-specific antibodies were detected in animals vaccinated with inactivated BoHV-1 LA strain at 14 dpv and were also positive by the end of the experimental period (data not shown).
Clinical monitoring of animals was performed daily, starting the day of vaccination until the end of the post-challenge observational period. No animals exhibited signs of BoHV-1 disease after vaccination. Bilateral nasal serous discharge was detected in the BoHV-1ΔgEβgal group at 2 days post-challenge (dpc) and for 11 days virus shedding was detected, with a maximum mean titer of 1.3 TCID50/ml at 8 dpc. In the BoHV-1 LA group, nasal discharge was mucous or serous. Virus shedding in mock-vaccinated animals peaked at 8 dpc (6.1 TCID50/ml) and serous to mucous nasal discharge lasted approximately 2 weeks. The protective responses were statistically different (p < 0.001) between vaccinated vs. mock-vaccinated animals, while no significant differences were found between animals vaccinated either BoHV-1ΔgEβgal or BoHV-1 LA.
Assessment of efficacy BoHV-1ΔgEβgal virus as a live attenuated vaccine
Animals involved in this assessment were randomly allotted into five groups of five cattle each. Groups 1, 2 and 3 received 4 ml of 108.25 TCID50/ml of BoHV-1ΔgEβgal virus by the IN, IM and IV routes, respectively. Group 4, the sentinel group, did not receive vaccine or challenge virus, but was housed with vaccinated animals beginning at 3 dpv, to evaluate horizontal transmission. Group 5 consisted of mock-vaccinated calves.
BoHV-1ΔgEβgal virus was shown to be attenuated. All animals vaccinated with BoHV-1ΔgEβgal, regardless of the inoculation route, exhibited minimal clinical symptoms of infection, with serous rhinitis as the only observed indicator of disease. No apathy, depression or loss of appetite was observed in these calves and their body temperatures never exceeded 40°C. Additionally, no detectable BoHV-1ΔgEβgal virus was found in the nasal or ocular secretions of the vaccinated calves. Only two animals belonging to the IN group shed virus, with viral titers of 1.5 TCID50/ml at 3 dpv, likely due to the existence of residual virus from the vaccination. No virus shedding was detected in the sentinel animals.
Analysis of the antibody response in animals vaccinated with BoHV-1ΔgEβgal indicated that detection of antibodies, measured by ELISA, started at 19 dpv in those vaccinated either IM or IV, while those vaccinated IN began exhibiting detectable antibody responses at 34 dpv, with significantly lower titers (p < 0.001) compared to the IM- and IV-vaccinated groups. On the day of challenge (42 dpv), the average antibody titers were 0.7 (±1.2) in the IN-vaccinated group and 2.36 (±1.2) and 2.05 (±0.3) in the IM- and IV-vaccinated groups respectively (Figure 3b). After challenge, antibody levels increase for all groups, reaching their maximal levels at 56 dpv with values of 3.7 (±0.3) for the IN-vaccinated group and 3.88 (±0.26) for the IM-vaccinated group (data not shown). While in the mock-vaccinated group animals displayed average antibody titers of 3.04 (±0.29) at 30 dpc, no antibodies were detected during the entire post-vaccination period in the sentinel group. Antibody responses were statistically different (p < 0.001) between IM/IV- vs. IN-vaccinated groups, and between vaccinated vs. mock-vaccinated animals, while no significant differences were found between animals vaccinated either IM or IV.
In agreement to the presence of total BoHV-1 antibodies, detection of virus neutralizing antibodies (VN) started at 19 dpv in animals vaccinated IM and IV. Titers found for IM and IV groups were significantly higher than in the IN-vaccinated group (p < 0.001). No VN titers were detected in the IN-vaccinated, mock-vaccinated or sentinel groups (Figure 3a).
At 14 dpv, all three groups of animals vaccinated with BoHV-1ΔgEβgal were found negative for presence of gE specific antibodies. After challenge with BoHV-1 LA strain, only animals from two vaccinated groups (IN and IM) turned to be positive for the presence of gE-specific antibodies.
The BoHV-1 specific T lymphocyte stimulation was evaluated using the LPT. At 7 dpv, the percentages of calves with a positive response to the LPT assay depended on the infection route. In the BoHV-1ΔgEβgal IN group, all calves produced a positive LPT response, while 60% and 20% of the IM- and IV-vaccinated groups were positive responders, respectively (Figure 4a). At 72 dpv (30 dpc), a positive response was seen in 80% of the calves in the IN-vaccinated group, and in 40% of the IM-vaccinated group (data not shown). The results of IFNγ production were in agreement with the data obtained with the LPT. When the production of IFNγ was evaluated at 7 dpv the calves that received the vaccine by IN spray demonstrated greater levels of IFNγ compared to those which received the IM vaccine (Figure 4b). The levels of IFN-γ were significantly higher (p < 0.05) in those animals that received the live virus vaccine by IM and IN routes, than those receiving the inactivated virus vaccine. Surprisingly, no detectable INF-γ response was found for the group vaccinated via IV.
Clinical analysis of the mock-vaccinated animals demonstrated the presence of symptoms, characterized by bilateral serous rhinitis observed at 2 dpc that increased in severity, as manifested by severe seromucous rhinitis (score 2–4) by 8–11 dpc, returning to normal by 22 dpc. All vaccinated animals, regardless of the route of inoculation, displayed significantly less severe symptoms, suffering slight serous rhinitis (score 1 to 2) or absence of rhinitis (score 0) (p < 0.001) in comparison with the mock-vaccinated group (Figure 5b). No apathy or loss of appetite was registered in the vaccinated animals.
Safety of BoHV-1ΔgEβgal LAV in pregnant animals
The pregnant cows that received the BoHV-1ΔgE-βgal virus by the IV route did not present abortions and all reached labor successfully. Animals only presented a transient and slight symptom manifestation of after the inoculation, without loss of appetite, depression or rise of body temperature. All the births reached term and none of the newborn calves showed detectable viral titers in their nasal secretions. Since their ninth day of life, we were able to detect in blood serum a titer of 1.6 of specific antibodies against BoHV-1 indicating the absorption of specific immunoglobulins from the maternal colostrum. BoHV-1ΔgE-βgal was shown to be completely innocuous not causing adverse collateral effects abortions/mummifications. Pregnant cows showed BoHV-1 specific antibody titers (≥ 1.6) until day 370 pv (data not shown). In addition, the LAV inoculated by IV route (group 3) induced long term immunity, since antibodies were detected during up to 370 days after a single immunization.
We describe here the development of a βgal-expressing gE-mutated BoHV-1 strain (BoHV-1ΔgEβgal). We characterized the use of BoHV-1ΔgEβgal as an immunogen in the formulation of both inactivated and LAV against BoHV-1. It is shown that BoHV-1ΔgEβgal, when used in either formulation, elicits an efficient immune response that protects animals against challenge with virulent wild-type BoHV-1. Importantly, antibody responses induced by BoHV-1ΔgEβgal virus (inactivated or live) can be serologically distinguished from those induced by wild-type virus, even at long term time-points after being exposed to infectious virus (30 dpc).
The viral gE ORF in BoHV-1ΔgEβgal was completely removed with the exception of the first 23 bp in its 5′ end and the last 67 bp in its 3′ end, and the β-gal gene was inserted in its place. Thus, BoHV-1ΔgEβgal differs from the mutant virus previously described by van Engelenburg et al., which carries a deletion of the complete gE gene based on the Lam strain ; from the mutant described by Rebordosa et al. and from the recombinant strain developed by Chowdhury et al. that contains 372 of the 575 aa of gE .
The βgal marker gene was chosen to be incorporated in the genome in order to facilitate the identification of the virus both for selection of recombinant clones and for the potential use in identification of the agent in samples derived from vaccinated animals. Removing the whole gE ORF constitutes a safety feature of the novel BoHV-1ΔgEβgal strain which also resulted in virulence attenuation. Due to the length of the insert, the addition of a βgal expressing cassette (4.5 kb) reduces to the minimum the probability of reversion to wild type forms of the BoHV-1.
Despite efforts made to generate a revertant, we were not able to obtain one from BoHV-1ΔgEβgal. Thus, the parental strain BoHV-1 LA was used as control for all vaccination experiments.
The vaccination schedule followed for testing efficacy for the inactivated vaccines was based on the official schedule of vaccination using inactivated vaccines against IBR disease (National Sanitary Service, SENASA). The official schedule mentioned involves first vaccination and a booster immunization after 21 days. It is known that 6 months after immunization with an inactivated BoHV-1 vaccine, virus-specific antibodies drop to a minimum value. In order to work with the maximum astringency, the calves were maintained and monitored during 6 months until challenge. On the other hand, manipulation of animals immunized using a LAV is considered a biohazard by the official authorities (National Advisory Commission of Agronomic Biotechnology, CONABIA). Thus, the experiments should be performed in closure and only after obtaining the corresponding authorization. For that, animals were maintained in a Type II biosafety facility. The experiment lasted the minimum period of time (42 days) enough for the vaccinated animals to develop a detectable immune response of a similar level to the one found in the field.
Inactivated BoHV-1ΔgEβgal displayed similar virus shedding period and titers as those recorded for the wild-type-based inactivated vaccine. These results are comparable to those communicated by Bosch et al. and Kaashoek et al. and ourselves . A thorough evaluation of the specific BoHV-1 humoral and cellular immune responses demonstrates the antigenic integrity of the glycoprotein E-deleted bovine herpesvirus type 1 strain. Importantly, BoHV-1ΔgEβgal-vaccinated bovines were easily differentiated from BoHV-1 LA-vaccinated animals, mock-vaccinated and BoHV-1-challenged animals, indicating the efficacy of inactivated BoHV-1ΔgEβgal as a marker vaccine.
Significantly, BoHV-1ΔgEβgal induced an antibody response that could easily be differentiated from that elicited by parental wild-type BoHV-1 LA virus. During the post-vaccination period of both inactivated and LAV BoHV-1ΔgEβgal studies, no anti-gE antibodies were detected until after challenge with the wild-type BoHV-1 virus, thus demonstrating its suitability as a DIVA marker vaccine.
The aim of the present work was to evaluate safety in terms of vertical or horizontal spreading of a novel BoHV-1 marker strain. Thus, an extremely high dose of BoHV-1ΔgEβgal was used for immunization. The minimum immunogenic and protective dose for its use in a commercial vaccine will be determined in future experiments. Live BoHV-1ΔgEβgal exhibits a noticeable attenuation, no virus was detected in nasal secretions during the post-vaccination period. This performance was better than other BoHV-1 recombinant strains containing gE deletions [2, 32, 33], which showed virus shedding from 104 to 106 TCID50/ml in a period from 6 to 8 days post-immunization. In order be considered safe, a LAV should not perpetuate in the cattle population . Strube et al. reported that although the gE-deleted IBR vaccine strain Difivac® may be shed by immunized animals, it has a limited ability to pass from animal to animal . In our study, although a high dose of virus was used to inoculate the animals (108.25 TCID50/ml), no BoHV-1ΔgEβgal was recovered from the nasal secretions of vaccinated or sentinel animals although both groups cohabitated up to the 42 dpv. Furthermore, BoHV-1ΔgEβgal IV immunized pregnant cows did not transmit the recombinant virus to their newborns.
The IV route of inoculation is usually considered the most aggressive immunization or infection method during pregnancy, since it represents a direct access of any pathogen or drug to critical organs (ie, spleen, liver, lungs), and thus is the route of choice to test drug safety. Safety assays performed in pregnant cows demonstrated that vertical spreading of BoHV-1ΔgEβgal was null and newborn calves born to infected mothers showed detectable levels of anti-BoHV-1 maternal antibodies by day 9 after birth.
Two important features should be considered when comparing our results to those from Mars et al. their mutant virus did not carry a deletion of the complete gE ORF and cattle used in that study were 4 weeks-old calves . Similar results were reported by van der Poel et al. using a BoHV-1ΔgE strain inoculated intramuscularly . Once in the animals, BoHV-1ΔgEβgal showed absence of horizontal and vertical spreading most probably related to the low replication levels of the recombinant strain, although this should be clarified by future pathogenicity, latency and reactivation experiments.
Protection against challenge induced by the recombinant virus was evaluated in terms of reduction of clinical disease and, most importantly, reduction of shedding of challenge virus. Only half of the IM- or IN-vaccinated and challenged animals excreted virus, with titer values of 102.6 to 105.5 TCID50/ml during a 2 day period. The levels of excreted virus in a post-challenge period were similar to those reported by other authors [2, 11, 15, 17, 18, 33, 35]. Even though animals vaccinated with inactivated BoHV-1ΔgEβgal showed higher VN titers than those immunized with live attenuated virus (IM or IN routes), no differences were found on virus shedding following BoHV-1 viral challenge. Remarkably, despite the fact that no detectable VN titers were found in circulating blood, the animals vaccinated by intranasal route with BoHV-1ΔgEβgal virus were protected against challenge. This result may probably related to the local induction of virus-specific immunity, as mentioned for individuals immunized with the inactivated BoHV-1ΔgEβgal virus, but needs to be further confirmed.
As a whole, our results showed that the BoHV-1ΔgEβgal may be used both as an inactivated immunogen or as a LAV against BoHV-1 infection in cattle. This recombinant virus elicited an efficient immune response with both strategies, which can protect animals from challenge with virulent wild-type BoHV-1 and may be serologically differentiated from that induced by wild-type virus. Safety assays demonstrated that BoHV-1ΔgEβgal was not horizontally or vertically transmitted when administered as a LAV, even when very high doses were utilized. The minimum immunogenic and protective dose for its use in a commercial vaccine will be determined in future experiments.
The BoHV-1ΔgEβgal strain is completely safe in terms of transmission to unvaccinated animals or environmental dissemination; BoHV-1ΔgEβgal is absolutely innocuous in pregnant cows and behaves as an attenuated BoHV1 strain in calves. Also, BoHV-1ΔgEβgal is protective against viral challenge and acts as an efficacious marker vaccine, since no antibodies were detected against gE protein during the post-vaccination period. Therefore, the new vaccine strain described here provides a useful combination of safety, attenuation, immunogenicity and DIVA capability.
Special thanks to Dr. F. Maliandi for his constant support during the project. This research was supported by grant BID 802 OC-AR PMT/PIT n° 053 from SECYT- INTA-San Jorge Bagó, Argentina. We particularly thank Melanie Prarat and Dr. Mariano Perez Filgueira for the editing of the manuscript.
- Jones C, Chowdhury S: A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines. Anim Health Res Rev/Conference of Research Workers in Animal Diseases. 2007, 8 (2): 187-205. 10.1017/S146625230700134X.View ArticleGoogle Scholar
- Kaashoek MJ, van Engelenburg FA, Moerman A, Gielkens AL, Rijsewijk FA, van Oirschot JT: Virulence and immunogenicity in calves of thymidine kinase- and glycoprotein E-negative bovine herpesvirus 1 mutants. Vet Microbiol. 1996, 48 (1–2): 143-153.View ArticlePubMedGoogle Scholar
- Tikoo SK, Campos M, Babiuk LA: Bovine herpesvirus 1 (BHV-1): biology, pathogenesis, and control. Adv Virus Res. 1995, 45: 191-223.View ArticlePubMedGoogle Scholar
- Ellis JA: Update on viral pathogenesis in BRD. Anim Health Res Rev/Conference of Research Workers in Animal Diseases. 2009, 10 (2): 149-153. 10.1017/S146625230999020X.View ArticleGoogle Scholar
- Muylkens B, Thiry J, Kirten P, Schynts F, Thiry E: Bovine herpesvirus 1 infection and infectious bovine rhinotracheitis. Vet Res. 2007, 38 (2): 181-209. 10.1051/vetres:2006059.View ArticlePubMedGoogle Scholar
- Babiuk LA, van Drunen L, van den Hurk S, Tikoo SK, Lewis PJ, Liang X: Novel viral vaccines for livestock. Vet Immunol Immunopathol. 1996, 54 (1–4): 355-363.View ArticlePubMedGoogle Scholar
- van Oirschot JT, Kaashoek MJ, Rijsewijk FA: Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Vet Microbiol. 1996, 53 (1–2): 43-54.View ArticlePubMedGoogle Scholar
- Muylkens B, Meurens F, Schynts F, Farnir F, Pourchet A, Bardiau M, Gogev S, Thiry J, Cuisenaire A, Vanderplasschen A, et al: Intraspecific bovine herpesvirus 1 recombinants carrying glycoprotein E deletion as a vaccine marker are virulent in cattle. J Gen Virol. 2006, 87 (Pt 8): 2149-2154.View ArticlePubMedGoogle Scholar
- van Engelenburg FA, Kaashoek MJ, Rijsewijk FA, van den Burg L, Moerman A, Gielkens AL, van Oirschot JT: A glycoprotein E deletion mutant of bovine herpesvirus 1 is avirulent in calves. J Gen Virol. 1994, 75 (Pt 9): 2311-2318.View ArticlePubMedGoogle Scholar
- Rebordosa X, Pinol J, Perez-Pons JA, Lloberas J, Naval J, Serra-Hartmann X, Espuna E, Querol E: Glycoprotein E of bovine herpesvirus type 1 is involved in virus transmission by direct cell-to-cell spread. Virus Res. 1996, 45 (1): 59-68. 10.1016/0168-1702(96)01353-6.View ArticlePubMedGoogle Scholar
- Kaashoek MJ, Rijsewijk FA, Ruuls RC, Keil GM, Thiry E, Pastoret PP, Van Oirschot JT: Virulence, immunogenicity and reactivation of bovine herpesvirus 1 mutants with a deletion in the gC, gG, gI, gE, or in both the gI and gE gene. Vaccine. 1998, 16 (8): 802-809. 10.1016/S0264-410X(97)00269-7.View ArticlePubMedGoogle Scholar
- Jacobs L, Kimman TG: Epitope-specific antibody response against glycoprotein E of pseudorabies virus. Clin Diagn Lab Immunol. 1994, 1 (5): 500-505.PubMed CentralPubMedGoogle Scholar
- Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC: Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J Virol. 1994, 68 (2): 834-845.PubMed CentralPubMedGoogle Scholar
- Rijsewijk FAM, Kaashoek MJ, Madic J, Paal H, Ruuls R, van Engelenburg F, van Oirschot JT: In vivo and in vitro role of the non-essential glycoprotein gC, gG, gI and gE of bovine herpesvirus 1. Proccedings of the symposium on IBR and other Rumiant Herpesvirus infections (abstract). 1995, Liege Belgium: European Society for Veterinary Virology, 27.Google Scholar
- Kaashoek MJ, Moerman A, Madic J, Rijsewijk FA, Quak J, Gielkens AL, van Oirschot JT: A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine. 1994, 12 (5): 439-444. 10.1016/0264-410X(94)90122-8.View ArticlePubMedGoogle Scholar
- Kaashoek MJ, Moerman A, Madic J, Weerdmeester K, Maris-Veldhuis M, Rijsewijk FA, van Oirschot JT: An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine. 1995, 13 (4): 342-346. 10.1016/0264-410X(95)98254-8.View ArticlePubMedGoogle Scholar
- Strube W, Auer S, Block W, Heinen E, Kretzdorn D, Rodenbach C, Schmeer N: A gE deleted infectious bovine rhinotracheitis marker vaccine for use in improved bovine herpesvirus 1 control programs. Vet Microbiol. 1996, 53 (1–2): 181-189.View ArticlePubMedGoogle Scholar
- Bosch JC, Kaashoek MJ, Kroese AH, van Oirschot JT: An attenuated bovine herpesvirus 1 marker vaccine induces a better protection than two inactivated marker vaccines. Vet Microbiol. 1996, 52 (3–4): 223-234.View ArticlePubMedGoogle Scholar
- Bosch JC, Kaashoek MJ, van Oirschot JT: Inactivated bovine herpesvirus 1 marker vaccines are more efficacious in reducing virus excretion after reactivation than a live marker vaccine. Vaccine. 1997, 15 (14): 1512-1517. 10.1016/S0264-410X(97)00092-3.View ArticlePubMedGoogle Scholar
- Bosch JC, De Jong MCM, Van Bree J, Van Oirschot JT: Quantification of transmission of bovine herpesvirus 1 in cattle vaccinated with marker vaccines Bovine herpesvirus 1 marker vaccines: tools for eradication?. PhD-thesis. the Netherlands: Utrecht University; 1997:54-65.Google Scholar
- Bosch JC, De Jong MC, Franken P: An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field. Vaccine. 1998, 16 (2–3): 265-271.View ArticlePubMedGoogle Scholar
- Kerkhofs P, Renjifo X, Toussaint JF, Letellier C, Vanopdenbosch E, Wellemans G: Enhancement of the immune response and virological protection of calves against bovine herpesvirus type 1 with an inactivated gE-deleted vaccine. Vet Rec. 2003, 152 (22): 681-686. 10.1136/vr.152.22.681.View ArticlePubMedGoogle Scholar
- Chowdhury SI, Kubin G, Ludwig H: Equine herpesvirus type 1 (EHV-1) induced abortions and paralysis in a Lipizzaner stud: a contribution to the classification of equine herpesviruses. Arch Virol. 1986, 90 (3–4): 273-288.View ArticlePubMedGoogle Scholar
- Chowdhury SI: Construction and characterization of an attenuated bovine herpesvirus type 1 (BHV-1) recombinant virus. Vet Microbiol. 1996, 52 (1–2): 13-23.View ArticlePubMedGoogle Scholar
- Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975, 98 (3): 503-517. 10.1016/S0022-2836(75)80083-0.View ArticlePubMedGoogle Scholar
- Romera SA, Hilgers LA, Puntel M, Zamorano PI, Alcon VL, Dus Santos MJ, Blanco Viera J, Borca MV, Sadir AM: Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle. Vaccine. 2000, 19 (1): 132-141. 10.1016/S0264-410X(00)00104-3.View ArticlePubMedGoogle Scholar
- Smitssart EN, Bratanich AC, Ruiz M, Sardi S, Blancoviera FJ, Leon E, Gonzalez O, Pugliese M, Schudel A, Schudel AA: Comportamiento inmunogénico de vacunas inactivadas polivalentes para herpesvirus bovino1. Rev Med Vet (Bs As). 1987, 3: 148-154.Google Scholar
- Parreño V, Romero SA, Makek L, Rodriguez D, Malacari D, Maidana S, Compaired D, Combessies G, Vena MM, Garaicoechea L, et al: Validation of an indirect ELISA to detect antibodies against BoHV-1 in bovine and guinea-pig serum samples using ISO/IEC 17025 standards. J Virol Methods. 2010, 169 (1): 143-153. 10.1016/j.jviromet.2010.07.014.View ArticlePubMedGoogle Scholar
- SAS Institute Inc: SAS/STAT User’s guide, Release 6.04. Cary, NC 27512, USA: SAS Institute; 1988.Google Scholar
- Rebordosa X, Pinol J, Perez-Pons JA, Lloberas J, Naval J, Querol E: Mapping, cloning and sequencing of a glycoprotein-encoding gene from bovine herpesvirus type 1 homologous to the gE gene from HSV-1. Gene. 1994, 149 (2): 203-209. 10.1016/0378-1119(94)90151-1.View ArticlePubMedGoogle Scholar
- Leung-Tack P, Audonnet JC, Riviere M: The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain). Virology. 1994, 199 (2): 409-421. 10.1006/viro.1994.1139.View ArticlePubMedGoogle Scholar
- Chowdhury SI, Ross CS, Lee BJ, Hall V, Chu HJ: Construction and characterization of a glycoprotein E gene-deleted bovine herpesvirus type 1 recombinant. Am J Vet Res. 1999, 60 (2): 227-232.PubMedGoogle Scholar
- Belknap EB, Walters LM, Kelling C, Ayers VK, Norris J, McMillen J, Hayhow C, Cochran M, Reddy DN, Wright J, et al: Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. Vaccine. 1999, 17 (18): 2297-2305. 10.1016/S0264-410X(98)00466-6.View ArticlePubMedGoogle Scholar
- Mars MH, de Jong MC, van Oirschot JT: A gE-negative BHV1 vaccine virus strain cannot perpetuate in cattle populations. Vaccine. 2000, 18: 2120-2124. 10.1016/S0264-410X(99)00556-3.View ArticlePubMedGoogle Scholar
- Strube W, Abar B, Bergle RD, Block W, Heinen E, Kretzdorn D, Rodenbach C, Schmeer N: Safety aspects in the development of an infectious bovine rhinotracheitis marker vaccine. Dev Biol Stand. 1995, 84: 75-81.PubMedGoogle Scholar
- van der Poel WH, Hage JJ: [Spread of an intramuscularly administered live gE-negative BHV1 marker vaccine in 2 cattle farms]. Tijdschr Diergeneeskd. 1998, 123 (4): 109-111.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.